The New York biotech will invest in and develop up to three drugs with Gensaic, an emerging startup aiming to use the viruses that infect bacteria to deliver genetic medicines.

The five-year partnership is one of many inked between the cancer center and drugmakers like Erasca, which is targeting a cellular pathway linked to many types of tumors.

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales. 

At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.

The decision will make a third vaccine available for children 12 to 17 years old in the U.S., giving them an option that doesn’t use the messenger RNA technology of shots by Pfizer and Moderna.

Fauci will leave his post as the director of the National Institute of Allergy and Infectious Diseases and as the president’s chief medical advisor.

European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December.

The revamped shot, which is adapted to the omicron variants now circulating, is key to the Biden administration’s plans for a fall vaccination campaign.

The agency suspended two trials of Pharvaris’ experimental treatment for hereditary angioedema after reviewing nonclinical data, the biotech said.

After spiking on news of the merger’s close, shares in the ADHD treatment developer fell sharply in trading Monday and again on Tuesday.

Leveraging adverse outcome pathways (AOPs) just got easier. Learn how to be a pro.

The Biden administration next week will provide 1.8 million doses of the Jynneos vaccine and 50,000 courses of antiviral Tpoxx to states and local governments.